Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free BPTSY Stock Alerts

Biophytis (BPTSY) Competitors

$0.25 0.00 (0.00%)
As of 05/1/2026
Compare

BPTSY vs. VCNX, INM, TRIB, MEHA, and VAXX

Should you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Vaccinex (VCNX), InMed Pharmaceuticals (INM), Trinity Biotech (TRIB), Functional Brands (MEHA), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry.

How does Biophytis compare to Vaccinex?

Biophytis (NASDAQ:BPTSY) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
Vaccinex N/A N/A -383.58%

Biophytis has higher earnings, but lower revenue than Vaccinex.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
Vaccinex$388K7.04-$20.25M-$48.27N/A

Biophytis has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.

In the previous week, Vaccinex had 2 more articles in the media than Biophytis. MarketBeat recorded 2 mentions for Vaccinex and 0 mentions for Biophytis. Vaccinex's average media sentiment score of 0.72 beat Biophytis' score of 0.00 indicating that Vaccinex is being referred to more favorably in the news media.

Company Overall Sentiment
Biophytis Neutral
Vaccinex Positive

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Vaccinex beats Biophytis on 5 of the 8 factors compared between the two stocks.

How does Biophytis compare to InMed Pharmaceuticals?

Biophytis (NASDAQ:BPTSY) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
InMed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Biophytis has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Biophytis has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -170.08%. Biophytis' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
InMed Pharmaceuticals -170.08%-73.63%-62.04%

InMed Pharmaceuticals has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
InMed Pharmaceuticals$4.94M0.50-$8.16M-$2.89N/A

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled InMed Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Biophytis Neutral
InMed Pharmaceuticals Neutral

Summary

Biophytis beats InMed Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Biophytis compare to Trinity Biotech?

Trinity Biotech (NASDAQ:TRIB) and Biophytis (NASDAQ:BPTSY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Biophytis has a net margin of 0.00% compared to Trinity Biotech's net margin of -85.36%.

Company Net Margins Return on Equity Return on Assets
Trinity Biotech-85.36% N/A -36.62%
Biophytis N/A N/A N/A

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 3.7% of Biophytis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Trinity Biotech had 3 more articles in the media than Biophytis. MarketBeat recorded 3 mentions for Trinity Biotech and 0 mentions for Biophytis. Trinity Biotech's average media sentiment score of 0.67 beat Biophytis' score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the media.

Company Overall Sentiment
Trinity Biotech Positive
Biophytis Neutral

Biophytis has lower revenue, but higher earnings than Trinity Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trinity Biotech$43.78M0.05-$37.38M-$9.40N/A
BiophytisN/AN/A-$18.43MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Trinity Biotech beats Biophytis on 6 of the 9 factors compared between the two stocks.

How does Biophytis compare to Functional Brands?

Biophytis (NASDAQ:BPTSY) and Functional Brands (NASDAQ:MEHA) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Functional Brands has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
Functional Brands$6.61M0.33$760K$0.042.50

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Functional Brands'average media sentiment score.

Company Overall Sentiment
Biophytis Neutral
Functional Brands Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Functional Brands
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.1% of Biophytis shares are owned by institutional investors. 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
Functional Brands N/A N/A N/A

Summary

Functional Brands beats Biophytis on 3 of the 5 factors compared between the two stocks.

How does Biophytis compare to Vaxxinity?

Biophytis (NASDAQ:BPTSY) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Biophytis Neutral
Vaxxinity Neutral

Biophytis has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -74.37, suggesting that its share price is 7,537% less volatile than the S&P 500.

0.1% of Biophytis shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 64.1% of Vaxxinity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
Vaxxinity N/A N/A N/A

Summary

Biophytis and Vaxxinity tied by winning 2 of the 4 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPTSY vs. The Competition

Export
MetricBiophytisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$586K$886.55M$6.25B$11.77B
Dividend YieldN/A4.84%2.74%5.26%
P/E RatioN/A0.9624.9123.23
Price / SalesN/A120.65504.5675.49
Price / CashN/A20.0743.3053.90
Price / Book-0.027.609.676.69
Net Income-$18.43M-$4.80M$3.55B$332.64M
7 Day PerformanceN/A-0.05%1.70%2.01%
1 Month PerformanceN/A5.50%5.62%9.19%
1 Year PerformanceN/A30.96%34.42%39.59%

Biophytis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPTSY
Biophytis
N/A$0.25
flat		N/AN/A$586KN/AN/A30
VCNX
Vaccinex
N/A$0.90
flat		N/AN/A$2.34M$388KN/A40
INM
InMed Pharmaceuticals
0.2424 of 5 stars		$0.70
-4.2%		N/AN/A$2.32M$4.94MN/A10
TRIB
Trinity Biotech
0.3539 of 5 stars		$0.63
-2.2%		N/AN/A$2.26M$49.41MN/A480
MEHA
Functional Brands
N/A$0.11
-1.8%		N/AN/A$2.25M$6.61M2.7033

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BPTSY) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel